Glenmark’s Ryaltris To Reach Western Europe Following Approvals

Indian Firm’s Marketing Plans Include Collaboration With Menarini Group

Glenmark is toasting another launch for the company’s Ryaltris novel treatment for allergic rhinitis, this time with plans to roll the product out in 17 countries across western Europe.

Europe_Map
Glenmark is “concluding the final, national phase of its marketing approval application process.” • Source: Shutterstock

Traditional generics player Glenmark Pharmaceuticals Limited has championed the company’s first innovative product approval in EU markets with its Ryaltris (olopatadine hydrochloride/mometasone furoate) 665mcg/25mcg nasal spray, which is to be sold through a combination of Glenmark’s internal sales force and licensing partner the Menarini Group.

The Indian firm is “concluding the final, national phase of its marketing approval application process,” to enable launch of the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin